All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
21 - 30 of 45 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Author(s): Calvo et al.
Open-label, Phase I dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab
Author(s): Gutierrez et al.
Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Author(s): Schoeps et al.
Predictive response biomarkers from Phase I clinical trial of SIRPalpha inhibitor, BI 765063, stand-alone and in combination with ezabenlimab, a PD-1 inhibitor, in patients with advanced solid tumors
Author(s): Champiat et al.
Presentation
Subgroup analysis of the ongoing Phase Ib DAREON®-7 study: Outcomes with first-line obrixtamig plus standard of care in neuroendocrine carcinomas by DLL3 expression status
Author(s): Capdevila et al.
A Phase I dose escalation trial of obrixtamig + ezabenlimab in patients with small cell lung cancer (SCLC) or other neuroendocrine carcinomas (NECs) expressing DLL3
Author(s): Mazières et al.
DAREON®-7: Phase I open-label dose-escalation/expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Capdevila et al.
Phase Ia results for systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: progress to date
Author(s): Parkes et al.
DAREON®-8: A Phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial
Author(s): Capdevila et al.